Bifogade filer
Kurs & Likviditet
Prenumeration
Kalender
2025-02-19 | Bokslutskommuniké 2024 |
2024-10-24 | Kvartalsrapport 2024-Q3 |
2024-08-21 | Kvartalsrapport 2024-Q2 |
2024-05-23 | Ordinarie utdelning AROC 0.00 SEK |
2024-05-22 | Årsstämma 2024 |
2024-05-03 | Kvartalsrapport 2024-Q1 |
2024-02-22 | Bokslutskommuniké 2023 |
2023-11-02 | Kvartalsrapport 2023-Q3 |
2023-08-23 | Kvartalsrapport 2023-Q2 |
2023-05-25 | Ordinarie utdelning AROC 0.00 SEK |
2023-05-24 | Årsstämma 2023 |
2023-05-03 | Kvartalsrapport 2023-Q1 |
2023-02-23 | Bokslutskommuniké 2022 |
2022-10-27 | Kvartalsrapport 2022-Q3 |
2022-08-17 | Kvartalsrapport 2022-Q2 |
2022-05-25 | Ordinarie utdelning AROC 0.00 SEK |
2022-05-24 | Årsstämma 2022 |
2022-04-29 | Kvartalsrapport 2022-Q1 |
2022-02-24 | Bokslutskommuniké 2021 |
2022-01-19 | Extra Bolagsstämma 2022 |
2021-11-12 | Kvartalsrapport 2021-Q3 |
2021-08-31 | Kvartalsrapport 2021-Q2 |
2021-06-03 | Extra Bolagsstämma 2021 |
2021-05-12 | Kvartalsrapport 2021-Q1 |
2021-05-07 | Ordinarie utdelning AROC 0.00 SEK |
2021-05-06 | Årsstämma 2021 |
2021-02-19 | Bokslutskommuniké 2020 |
2020-11-19 | Kvartalsrapport 2020-Q3 |
2020-08-20 | Kvartalsrapport 2020-Q2 |
2020-05-15 | Kvartalsrapport 2020-Q1 |
2020-05-07 | Ordinarie utdelning AROC 0.00 SEK |
2020-05-06 | Årsstämma 2020 |
2020-02-21 | Bokslutskommuniké 2019 |
2019-11-08 | Extra Bolagsstämma 2019 |
2019-11-05 | Kvartalsrapport 2019-Q3 |
2019-08-21 | Kvartalsrapport 2019-Q2 |
2019-05-17 | Ordinarie utdelning AROC 0.00 SEK |
2019-05-16 | Kvartalsrapport 2019-Q1 |
2019-05-16 | Årsstämma 2019 |
2019-02-22 | Bokslutskommuniké 2018 |
2018-11-09 | Kvartalsrapport 2018-Q3 |
2018-08-31 | Kvartalsrapport 2018-Q2 |
2018-06-18 | Ordinarie utdelning AROC 0.00 SEK |
2018-06-15 | Årsstämma 2018 |
2018-04-27 | Kvartalsrapport 2018-Q1 |
2018-02-22 | Bokslutskommuniké 2017 |
2017-11-23 | Kvartalsrapport 2017-Q3 |
2017-08-24 | Kvartalsrapport 2017-Q2 |
2017-05-19 | Ordinarie utdelning AROC 0.00 SEK |
2017-05-18 | Årsstämma 2017 |
2017-05-11 | Kvartalsrapport 2017-Q1 |
2017-02-16 | Bokslutskommuniké 2016 |
2016-11-17 | Kvartalsrapport 2016-Q3 |
2016-08-25 | Kvartalsrapport 2016-Q2 |
2016-05-19 | Ordinarie utdelning AROC 0.00 SEK |
2016-05-18 | Årsstämma 2016 |
2016-05-10 | Kvartalsrapport 2016-Q1 |
2016-02-16 | Bokslutskommuniké 2015 |
2015-11-10 | Kvartalsrapport 2015-Q3 |
2015-08-25 | Kvartalsrapport 2015-Q2 |
2015-06-04 | Ordinarie utdelning AROC 0.00 SEK |
2015-06-03 | Årsstämma 2015 |
2015-05-28 | Kvartalsrapport 2015-Q1 |
2015-02-17 | Bokslutskommuniké 2014 |
2014-11-18 | Kvartalsrapport 2014-Q3 |
2014-08-19 | Kvartalsrapport 2014-Q2 |
2014-05-08 | Ordinarie utdelning AROC 0.00 SEK |
2014-05-07 | Årsstämma 2014 |
2014-05-05 | Kvartalsrapport 2014-Q1 |
2014-02-18 | Bokslutskommuniké 2013 |
2013-11-27 | Kvartalsrapport 2013-Q3 |
2013-08-21 | Kvartalsrapport 2013-Q2 |
2013-05-06 | Ordinarie utdelning AROC 0.00 SEK |
2013-05-03 | Årsstämma 2013 |
2013-04-24 | Kvartalsrapport 2013-Q1 |
2013-02-19 | Bokslutskommuniké 2012 |
2012-11-20 | Kvartalsrapport 2012-Q3 |
2012-08-21 | Kvartalsrapport 2012-Q2 |
2012-06-13 | Ordinarie utdelning AROC 0.00 SEK |
2012-06-12 | Årsstämma 2012 |
2012-05-22 | Kvartalsrapport 2012-Q1 |
2012-03-05 | Extra Bolagsstämma 2012 |
2012-02-09 | Bokslutskommuniké 2011 |
2011-10-17 | Kvartalsrapport 2011-Q3 |
2011-08-17 | Kvartalsrapport 2011-Q2 |
2011-06-01 | Kvartalsrapport 2011-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
AroCell AB announced today that a dialogue has been held with the U.S. Food and Drug Administration (FDA) regarding the 510(k) submission that the company submitted on May 26, 2020. In the dialogue with the FDA, AroCell received questions regarding the 510(k) submission. AroCell intends to process the questions promptly and update the application within a few weeks.
"This type of dialogue with regulatory authorities is not uncommon when applying for 510(k). We have had a constructive dialogue with the FDA and we are now focusing on addressing the questions and updating the application in accordance with FDA recommendations," says Michael Brobjer, CEO of AroCell.
About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com
This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-09-22 17:00 CEST.